JP2020536123A - クロファジミンの吸入可能な組成物およびその使用方法 - Google Patents

クロファジミンの吸入可能な組成物およびその使用方法 Download PDF

Info

Publication number
JP2020536123A
JP2020536123A JP2020539683A JP2020539683A JP2020536123A JP 2020536123 A JP2020536123 A JP 2020536123A JP 2020539683 A JP2020539683 A JP 2020539683A JP 2020539683 A JP2020539683 A JP 2020539683A JP 2020536123 A JP2020536123 A JP 2020536123A
Authority
JP
Japan
Prior art keywords
clofazimine
pharmaceutical composition
composition according
dry powder
particles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020539683A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020536123A5 (https=
Inventor
ヒュー スマイス
ヒュー スマイス
アシュリー ブルノー
アシュリー ブルノー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System filed Critical University of Texas System
Publication of JP2020536123A publication Critical patent/JP2020536123A/ja
Publication of JP2020536123A5 publication Critical patent/JP2020536123A5/ja
Priority to JP2023145739A priority Critical patent/JP2023171770A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/46—Phenazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2020539683A 2017-10-02 2018-10-02 クロファジミンの吸入可能な組成物およびその使用方法 Pending JP2020536123A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023145739A JP2023171770A (ja) 2017-10-02 2023-09-08 クロファジミンの吸入可能な組成物およびその使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762566633P 2017-10-02 2017-10-02
US62/566,633 2017-10-02
PCT/US2018/053947 WO2019070693A1 (en) 2017-10-02 2018-10-02 COMPOSITION FOR INHALING CLOFAZIMINE AND METHODS OF USE

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023145739A Division JP2023171770A (ja) 2017-10-02 2023-09-08 クロファジミンの吸入可能な組成物およびその使用方法

Publications (2)

Publication Number Publication Date
JP2020536123A true JP2020536123A (ja) 2020-12-10
JP2020536123A5 JP2020536123A5 (https=) 2021-11-11

Family

ID=65995179

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020539683A Pending JP2020536123A (ja) 2017-10-02 2018-10-02 クロファジミンの吸入可能な組成物およびその使用方法
JP2023145739A Pending JP2023171770A (ja) 2017-10-02 2023-09-08 クロファジミンの吸入可能な組成物およびその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023145739A Pending JP2023171770A (ja) 2017-10-02 2023-09-08 クロファジミンの吸入可能な組成物およびその使用方法

Country Status (8)

Country Link
US (2) US20200297626A1 (https=)
EP (1) EP3691646A4 (https=)
JP (2) JP2020536123A (https=)
CN (1) CN111212645A (https=)
AU (2) AU2018345609A1 (https=)
BR (1) BR112020006609A2 (https=)
CA (1) CA3077421A1 (https=)
WO (1) WO2019070693A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112279815A (zh) * 2019-07-22 2021-01-29 中国食品药品检定研究院 一种氯法齐明盐类化合物及其制备方法和用途
CN121221570A (zh) * 2019-11-06 2025-12-30 曼金德公司 氯法齐明的组合物，含它们的组合，它们的制备方法，含它们的用途和治疗方法
AU2021263580A1 (en) * 2020-05-01 2022-11-24 Mannkind Corporation Clofazimine composition and method for the treatment or prophylaxis of viral infections
US11793808B2 (en) 2021-02-22 2023-10-24 Mannkind Corp. Compositions of clofazimine, combinations comprising them, processes for their preparation, uses and methods comprising them
US20240299379A1 (en) * 2021-06-01 2024-09-12 Board Of Regents, The University Of Texas System Compositions of clofazimine and amikacin for pulmonary administration in the treatment of respiratory diseases

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01254624A (ja) * 1988-02-26 1989-10-11 Fournier Innov & Synergie フェノフィブレートを含有する治療用組成物およびその製造方法
JPH069408A (ja) * 1992-04-15 1994-01-18 Ciba Geigy Ag イオン交換体を含むメタンジホスホン酸製剤
US20100330156A1 (en) * 2007-09-21 2010-12-30 The Johns Hopkins University Phenazine derivatives and uses thereof
JP2011513375A (ja) * 2008-03-04 2011-04-28 ブリタニア ファーマシューティカルズ リミテッド リン脂質結晶、その製造方法、及び損傷組織の治療におけるその使用
US20160220710A1 (en) * 2015-01-30 2016-08-04 The Regents Of The University Of Michigan Compositions and methods for delivering pharmaceutical agents

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2168571B1 (en) * 2000-11-30 2018-08-22 Vectura Limited Particles for use in a Pharmaceutical Composition
CN107596518B (zh) * 2012-02-29 2021-04-23 普马特里克斯营业公司 可吸入干粉剂
KR101466616B1 (ko) * 2012-10-11 2014-11-28 한미약품 주식회사 건조분말 흡입장치
WO2016081825A1 (en) * 2014-11-21 2016-05-26 KamTek, Inc. Methods and compositions for treating clostridium difficile associated disease
JP6773675B2 (ja) * 2015-03-11 2020-10-21 アレックザ ファーマシューティカルズ， インコーポレイテッド サーマルエアゾール凝縮プロセスのためのエアウェイにおける帯電防止材の使用
WO2016196401A1 (en) * 2015-05-29 2016-12-08 The Texas A&M University System Antimicrobial and anti-inflammatory compositions
JP6953414B2 (ja) * 2016-01-20 2021-10-27 フラリー パウダーズ エルエルシーＦｌｕｒｒｙ Ｐｏｗｄｅｒｓ，Ｌｌｃ 親油性成分を含む吸入に好適な分散性の噴霧乾燥粉末を製造する方法

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01254624A (ja) * 1988-02-26 1989-10-11 Fournier Innov & Synergie フェノフィブレートを含有する治療用組成物およびその製造方法
JPH069408A (ja) * 1992-04-15 1994-01-18 Ciba Geigy Ag イオン交換体を含むメタンジホスホン酸製剤
US20100330156A1 (en) * 2007-09-21 2010-12-30 The Johns Hopkins University Phenazine derivatives and uses thereof
JP2011513375A (ja) * 2008-03-04 2011-04-28 ブリタニア ファーマシューティカルズ リミテッド リン脂質結晶、その製造方法、及び損傷組織の治療におけるその使用
US20160220710A1 (en) * 2015-01-30 2016-08-04 The Regents Of The University Of Michigan Compositions and methods for delivering pharmaceutical agents

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
VERMA, R.K., ET AL., ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 57, no. 2, JPN6022037325, 2013, pages 1050 - 1052, ISSN: 0005056054 *

Also Published As

Publication number Publication date
WO2019070693A1 (en) 2019-04-11
AU2018345609A1 (en) 2020-04-16
AU2024205572A1 (en) 2024-08-22
JP2023171770A (ja) 2023-12-05
EP3691646A4 (en) 2021-06-30
US20200297626A1 (en) 2020-09-24
BR112020006609A2 (pt) 2020-10-06
CA3077421A1 (en) 2019-04-11
EP3691646A1 (en) 2020-08-12
US20240099967A1 (en) 2024-03-28
CN111212645A (zh) 2020-05-29

Similar Documents

Publication Publication Date Title
US20240099967A1 (en) Inhalable composition of clofazimine and methods of use thereof
JP7320485B2 (ja) アビラテロン酢酸エステル製剤
JP5727927B2 (ja) フルオロキノロンの肺送達
AU2011287711B2 (en) Dry powder formulation comprising a phosphodiesterase inhibitor
CN101222927B (zh) 气溶胶化的氟喹诺酮类药物及其应用
WO2007095156A2 (en) Taste masking of aerosolized fluoroquinolones
MX2007011502A (es) Formulaciones de antagonista del receptor de leucotrieno en nanoparticulas con corticosteroide.
US20160128972A1 (en) Method for preventing influenza virus infection by administering a dry powder pharmaceutical composition
JP6850524B2 (ja) 吸入用の乾燥粉末製剤
WO2016176552A1 (en) Dry power formulations for inhalation
WO2011052706A1 (ja) トラニラストの易溶性粉末吸入製剤
JP2014227371A (ja) 吸入用医薬組成物
AU2013203605B2 (en) Aerosolized fluoroquinolones and uses thereof
WO2022023456A1 (en) Pharmaceutical compositions comprising nano embedded microparticles and methods of use
EP4149422A1 (en) Inhalable lactose containing composition
US20240299379A1 (en) Compositions of clofazimine and amikacin for pulmonary administration in the treatment of respiratory diseases
US20250387326A1 (en) Crystalline pharmaceutical composition for inhalation comprising sugar and lipid composite particles and process for manufacture
HK1095266A1 (zh) 控释无菌阿立哌唑注射剂和方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200525

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210121

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210930

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210930

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220905

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221201

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230203

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230206

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230511